Lp(a) recommended for those at highest risk for CVD/CHD

The aims of the study were, first, to critically evaluate lipoprotein(a) as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies. The European Heart Journal researchers concluded that screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level below 50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction is highly recommended.

Steve - there's that cheap, effective B-vitamin niacin again.